Title: Multiple-Promoter Expression Cassettes for Simultaneous Delivery of RNAi Agents Targeted to Hepatitis C Virus
Patent Number: 7,727,970
Filed: March 4, 2005
Lead Inventor: Petrus Roelvink, Benitec
The invention, the patent's abstract states, "provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo."
Title: Inhibition of Autophagy Genes in Cancer Chemotherapy
Application Number: 20100129429
Filed: Nov. 3, 2006 PCT Filed: Nov. 3, 2006
Lead Inventor: Sharon Margaret Gorski, British Columbia Cancer Agency
The invention, the patent application's abstract states, comprises "compositions and methods for improving the therapeutic efficacy of various cancer treatments, for example endocrine therapy, chemotherapy, or radiation therapy, by inhibiting the expression of one or more genes involved in the cellular autophagy response. The compositions include … an siRNA directed against an Atg gene and may be used to inhibit expression of an Atg gene in a cell currently undergoing cancer therapy, or to treat, inhibit, or prevent cancer in a subject in combination with a cancer therapy."
Title: Targeted Intracellular Delivery of Antiviral Agents
Application Number: 20100129437
Filed: March 21, 2008 PCT Filed: March 21, 2008
Inventor: Pieter Jaap Gaillard, BBB Holding
"The invention relates to methods of targeted drug delivery of antiviral compounds, including … nucleic acid based drugs … or RNA molecules," the patent application's abstract states. "Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues, and organs, in particular to target sites within the central nervous system, into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues, and organs. … The antiviral compounds … are conjugated to ligands that facilitate the specific binding to and internalization by these receptors."
Title: Compounds and Methods for Peptide Ribonucleic Acid Condensate Particles for RNA Therapeutics
Application Number: 20100129460
Filed: Oct. 13, 2006 PCT Filed: Oct. 13, 2006
Lead Inventor: Roger Adami, Nastech Pharmaceutical (MDRNA)
The patent application, its abstract states, claims "compounds comprising condensed particles having diameters less than 1000 nm, wherein the particles comprise one or more double-stranded ribonucleic acids and one or more peptides. The compounds, compositions, and methods are useful for modulating gene expression by RNA interference."
Title: Compounds and Methods for Detecting Small RNAs and Uses Thereof
Application Number: 20100129822
Filed: Nov. 25, 2009
Lead Inventor: Amara Siva, Gen-Probe
The invention, the patent application's abstract states, comprises compositions and methods … for the detection of small RNA target nucleic acids, preferably miRNA target nucleic acids, wherein the compositions and methods provide for sensitive and specific detection of the target nucleic acids. The compositions and methods include using one or more of a first amplification oligomer that is preferably an extender primer, a target capture oligomer that is preferably at least partially double-stranded, a promoter primer/provider, a reverse primer that is preferably a universal primer, and a detection probe. The compositions and methods are useful for diagnostics, prognostics, monitoring the effectiveness of treatment, and/or determining a treatment."
Title: Methods for Disease Therapy
Application Number: 20100130526
Filed: June 1, 2009
Inventor: Gennadi Glinsky, Ordway Research Institute
The invention, the patent application's abstract states, "discloses disease-linked SNPs, microRNAs, and microRNA-targeted mRNAs relevant to the pathogenesis of several major human disorders including, but not limited to, multiple types of cancers, type II diabetes, type I diabetes, Crohn's disease, coronary artery disease, hypertension, rheumatoid arthritis, [and] bipolar disorder.
"Also provided are methods for the identification of disease phenotype-defining sets of SNPs, microRNAs, and mRNAs that are defined here as a consensus disease phenocode, as well as methods of using the information provided by these consensus disease phenocodes for various diagnostic, prognostic, and/or therapeutic applications," it adds.
Title: Methods of Treating Cancer Using siRNA Molecules Directed Against CD24
Application Number: 20100130587
Filed: Nov. 13, 2007 PCT Filed: Nov. 13, 2007
Lead Inventor: Nadir Arber, Tel Aviv Medical Center
The patent application, its abstract states, claims "a method of treating a CD24-related medical condition … [that] comprises administering to a subject in need thereof at least one siRNA molecule selected from [a predefined] group. Pharmaceutical compositions comprising same are also disclosed."
Title: Novel Lipid Formulations for Nucleic Acid Delivery
Application Number: 20100130588
Filed: April 15, 2009
Lead Inventor: Edward Yaworski, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
The invention "provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles," the patent application's abstract states. "More particularly, the … invention provides stable nucleic acid-lipid particles comprising a nucleic acid, methods of making the SNALP, and methods of delivering and/or administering the SNALP."
Title: RNA Interference-Mediated Inhibition of GRB2-Associated Binding Protein Gene Expression Using Short Interfering Nucleic Acid
Application Number: 20100130592
Filed: Dec. 17, 2009
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
"This invention relates to compounds, compositions, and methods useful for modulating GRB2-associated binding protein gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GRB2-associated binding protein gene expression and/or activity by RNA interference using small nucleic acid molecules. … The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease, inflammatory diseases or conditions, allergic diseases or conditions, or proliferative diseases or conditions."
Title: Polymeric Carrier for Delivery of Small Interfering RNA
Application Number: 20100130722
Filed: Jan. 21, 2010
Lead Inventor: Won Jong Kim, University of Utah
The patent application, its abstract states, claims "a carrier for delivering small interfering RNA into cells [comprised of] a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer."
Title: [Therapeutic] Compositions Comprising an RNAi Agent and a Neurotrophic Factor, and Methods of Use Thereof
Application Number: 20100132060
Filed: Jan. 3, 2008 PCT Filed: Jan. 3, 2008
Inventor: Eric Burright, Medtronic
"The invention provides novel combination therapies for treating neurodegenerative disease which comprise neurotrophic factors or suitable fragments thereof and agents capable of causing inhibition of a gene responsible for the neurodegenerative disease," the patent application's abstract states. "The invention provides novel nucleic acid sequences, methods, and systems suitable for applications of these combination therapies."